Tetanus-diphtheria toxoid vaccination in adults
- Patricia L Hibberd, MD, PhD
Patricia L Hibberd, MD, PhD
- Chief, Division of Global Health
- Massachusetts General Hospital for Children
Administration of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine is routinely recommended in children, with a single booster dose of a vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) recommended for 11- to 12-year-olds, followed by tetanus toxoid and the reduced diphtheria toxoid in the form of Td recommended at 10-year intervals throughout life (figure 1A-B). (See "Standard immunizations for children and adolescents", section on 'Diphtheria, tetanus, and/or pertussis vaccines' and "Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age" and "Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age".)
Despite these recommendations, immunity to tetanus and diphtheria continues to wane among adults in the United States. The magnitude of this effect was illustrated in a cross-sectional survey of individuals in the United States who were examined between 1988 and 1994 . Only 47 percent of adults over the age of 20 had protective antibody to both diseases and only 63 percent of adults with immunity to tetanus also had protective antibody to diphtheria. In comparison, 91 percent of children from 6 to 11 years of age had protective antibody to both diseases. Immunity to pertussis also wanes among adolescents and adults. (See "Microbiology, epidemiology, and pathogenesis of Bordetella pertussis infection".)
The rationale and risk-benefit considerations for the administration of tetanus-diphtheria toxoid (Td) vaccination in adults will be reviewed here. The use of the booster vaccine containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), immunizations in pregnant women, and the general principles behind adult immunization are discussed separately. (See "Immunizations during pregnancy", section on 'Tetanus, diphtheria, pertussis (Tdap)' and "Approach to immunizations in healthy adults" and "Treatment and prevention of Bordetella pertussis infection in adolescents and adults", section on 'Prevention'.)
EPIDEMIOLOGY OF DISEASE
The epidemiology of tetanus and diphtheria is discussed in detail elsewhere but will be briefly reviewed here. Both infections are completely preventable with safe and effective toxoid vaccines.
Tetanus — Because of near universal vaccination of children with tetanus toxoid, the incidence of tetanus in the United States and the rest of the developed world has dropped dramatically and steadily since 1940. During the period between 2001 and 2008, the United States Centers for Disease Control and Prevention (CDC) reported that there were 233 cases of tetanus in the United States, with an annual incidence of 0.10 cases/million population overall and 0.23 cases/million among individuals ≥65 years of age . Unpredictable acute injuries remain the major cause of tetanus in the United States.
- McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136:660.
- Centers for Disease Control and Prevention (CDC). Tetanus surveillance --- United States, 2001-2008. MMWR Morb Mortal Wkly Rep 2011; 60:365.
- Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995; 332:761.
- Singleton JA, Greby SM, Wooten KG, et al. Influenza, pneumococcal, and tetanus toxoid vaccination of adults --- United States, 1993--1997. MMWR Surveill Summ 2000; 49:39.
- Maple PA, Efstratiou A, George RC, et al. Diphtheria immunity in UK blood donors. Lancet 1995; 345:963.
- CDC - Vaccination Coverage in the U.S. http://www.cdc.gov/vaccines/imz-managers/coverage/imz-coverage.html (Accessed on April 17, 2014).
- Kim DK, Bridges CB, Harriman KH, Advisory Committee on Immunization Practices. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2015*. Ann Intern Med 2015; 162:214.
- Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:13.
- Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.
- US Food and Drug Administration. Adacel (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed). http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481.htm (Accessed on April 08, 2014).
- Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62:131.
- Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus. Lancet 2014.